Cargando…

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients

Detalles Bibliográficos
Autores principales:	Schiano di Cola, Francesca, Caratozzolo, Salvatore, Bolchini, Marco, Ceccardi, Giulia, Cortinovis, Matteo, Liberini, Paolo, Padovani, Alessandro, Rao, Renata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Short Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385831/ https://www.ncbi.nlm.nih.gov/pubmed/35618933 http://dx.doi.org/10.1007/s10072-022-06154-0

Ejemplares similares

Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine
por: di Cola, Francesca Schiano, et al.
Publicado: (2023)

Photophobia and migraine outcome during treatment with galcanezumab
por: Schiano di Cola, Francesca, et al.
Publicado: (2023)

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment
por: Schiano di Cola, Francesca, et al.
Publicado: (2019)

Onabotulinumtoxin-a during COVID-19 pandemic: Long-term efficacy in chronic migraine
por: Locatelli, Martina, et al.
Publicado: (2021)

Post COVID-19 vaccination headache: A clinical and epidemiological evaluation
por: Ceccardi, Giulia, et al.
Publicado: (2022)

Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021)

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
por: Martelletti, Paolo
Publicado: (2020)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
por: Caronna, Edoardo, et al.
Publicado: (2021)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017)

Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine
por: Lovato, Andrea, et al.
Publicado: (2023)

Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review
por: Aditya, Suruchi, et al.
Publicado: (2023)

Serotonin and CGRP in Migraine
por: Aggarwal, Milan, et al.
Publicado: (2012)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
por: Han, Lin, et al.
Publicado: (2019)

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
por: Vandervorst, Fenne, et al.
Publicado: (2021)

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
por: Simioni, Caio Vinicius de Meira Grava
Publicado: (2022)

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
por: Kubota, Gabriel Taricani
Publicado: (2022)

Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
por: Scuteri, Damiana, et al.
Publicado: (2021)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
por: Barbanti, Piero, et al.
Publicado: (2022)

Gender aspects of CGRP in migraine
por: Labastida-Ramírez, Alejandro, et al.
Publicado: (2017)

CGRP and the Trigeminal System in Migraine
por: Iyengar, Smriti, et al.
Publicado: (2019)

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
por: Sevivas, Hugo, et al.
Publicado: (2022)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
por: Ailani, Jessica, et al.
Publicado: (2021)

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
por: Argyriou, Andreas A., et al.
Publicado: (2022)

CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?
por: Kamm, Katharina
Publicado: (2022)

CGRP and migraine: neurogenic inflammation revisited
por: Geppetti, P., et al.
Publicado: (2005)

CGRP receptors and TRP channels in migraine
por: Geppetti, Pierangelo, et al.
Publicado: (2015)

CGRP as a Migraine Inducing Substance
por: Olesen, J., et al.
Publicado: (2001)

Dural Immune Cells, CGRP, and Migraine
por: Balcziak, Louis K., et al.
Publicado: (2022)

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy
por: Mullin, Kathleen, et al.
Publicado: (2020)

Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review
por: Albanese, Maria, et al.
Publicado: (2022)

Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
por: Cohen, Fred, et al.
Publicado: (2022)

Migraine therapeutics differentially modulate the CGRP pathway
por: Bhakta, Minoti, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gehaitudmu8dp3stuo3f9ptgge